OriBiotech Profile Banner
Oribiotech Profile
Oribiotech

@OriBiotech

Followers
526
Following
243
Media
853
Statuses
1K

Ori Biotech is an innovator in Cell and Gene Therapy manufacturing, delivering scalable solutions to address the critical needs of therapeutics developers.

London and New Jersey
Joined December 2019
Don't wanna be here? Send us removal request.
@OriBiotech
Oribiotech
3 years
We are excited to announce a partnership with CTMC, a joint @IncResilience & @MDAndersonNews venture, to accelerate novel cell therapy delivery. 🙌. We are looking forward to working together to enable widespread patient access to cell therapies. ➡️
Tweet media one
0
0
11
@OriBiotech
Oribiotech
4 hours
@GENbio @Ori_JCFoster Hear more from Jason on the factors holding CGT back via @WSJCustom:
0
0
0
@OriBiotech
Oribiotech
4 hours
Bioprocessing platforms that enable flexibility and scalability are critical to meet patient demand for CGTs. With @GENbio, @Ori_JCFoster discussed how we’re partnering with best-of-breed providers and technologies to expand flexibility for developers⬇️.
Tweet media one
1
0
0
@OriBiotech
Oribiotech
1 day
🔬 @abbvie's $2.1B acquisition of @capstantx highlights continued momentum for in vivo CAR-T. By reprogramming T cells inside the body using mRNA-LNPs, the approach could sidestep manufacturing bottlenecks and make CAR-T more accessible. Read more:
Tweet media one
0
1
1
@OriBiotech
Oribiotech
2 days
Capital-intensive manufacturing with low yields continues to challenge CGT delivery. @AKAarsalan, Founder of @endpts, joined @Ori_JCFoster on the Ori Spotlight Podcast to discuss how rethinking manufacturing will allow the industry to move forward. 🎧
0
0
1
@OriBiotech
Oribiotech
3 days
Attending Boston for the 4th Process Development for Cell Therapies Summit? Meet our VP of BD, Kale Feeter!. 📅 July 9–11.📍 Revere Hotel Boston Common, USA. Connect with Kale to learn more about how IRO® can help you scale the impact of your therapies ➡️
0
0
0
@OriBiotech
Oribiotech
6 days
The clinical success of CGTs alone is insufficient if manufacturing and commercialization capabilities are not robust and scalable. Read our whitepaper to learn how automated and scalable manufacturing can drive commercial success and patient access➡️
0
0
0
@OriBiotech
Oribiotech
7 days
Jennifer Le’s lupus diagnosis in 2016 brought ER visits, fatigue, and concerns about being able to start a family. In 2023, she joined a CAR-T trial and 6 months later, she’s back at work, and planning for the future. 🔗
0
0
1
@OriBiotech
Oribiotech
8 days
Researchers at @KingsCollegeLon have engineered CAR-T cells to use fructose when glucose is scarce in solid tumors. This modification preserves anti-tumor activity which could help improve CAR-T efficacy against solid tumors. 🔗
0
0
0
@OriBiotech
Oribiotech
9 days
📊 One of CGT’s biggest hurdles isn’t science. It’s economics. @endpts founder @AKAarsalan joins @Ori_JCFoster on the Ori Spotlight Podcast to talk investor sentiment, stalled assets, and why execution will define CGT’s next chapter. Listen now:.🎧
Tweet media one
0
0
2
@OriBiotech
Oribiotech
10 days
In our webinar with @CGT_Insights, our CCO @Thomas_Heathman and Senior Scientist Hamza Patel, explored how fluid dynamics can accelerate CGT development and support closed, scalable manufacturing from process development to commercial scale. Watch here:
0
0
0
@OriBiotech
Oribiotech
13 days
Rehan and Parimala are South India’s longest-known CAR-T survivors. Treated at @NarayanaHealth after years of failed therapies, both are now in remission and rebuilding their life. A reminder of what’s possible when CGTs are truly accessible. 🔗
0
0
1
@OriBiotech
Oribiotech
14 days
Developers need #Manufacturing solutions that evolve with the science, support rapid iteration & scale across therapy portfolios. That’s why we built IRO® – a flexible, modular platform to support development from R&D through to GMP. Read our Whitepaper➡️
0
0
0
@OriBiotech
Oribiotech
15 days
🎙️ Our CEO @Ori_JCFoster is taking to the stage for @somXhealthtech's Healthtech Talks with @googlecloud, where he'll join a panel exploring the role of #tech in enabling patient impact at scale. 📆 June 30, 18:30 BST.📍London. Register your interest:
0
0
0
@OriBiotech
Oribiotech
16 days
Read the full paper ➡️
0
0
0
@OriBiotech
Oribiotech
16 days
How will AI, ML, and digital impact the CGTs?. Our Director, Technical Solutions, Keara Trinkle, co-authored a recently published paper in Cytotherapy examining how these technologies can enhance #Manufacturing efficiency and increase market access ⬇️.
1
0
0
@OriBiotech
Oribiotech
17 days
Scientific momentum in CGTs is high, but we’re yet to see impact at scale. At @alliancerm @CGTCatapult's Workshop, @Ori_JCFoster joined the ‘Robots, Automation, and AI/ML’ panel to explore how tech can help the industry design for scale and deliver on CGT's commercial potential.
Tweet media one
Tweet media two
0
1
1
@OriBiotech
Oribiotech
20 days
@Ori_JCFoster @WSJCustom Read the full interview:
0
0
0
@OriBiotech
Oribiotech
20 days
Scientific breakthroughs mean little without scalable #Manufacturing. As @Ori_JCFoster shared with @WSJCustom, <20% of eligible patients can access CGTs because too often, commercial production is an afterthought. We need to design for scale and throughput from day 1.
Tweet media one
1
0
0
@OriBiotech
Oribiotech
21 days
In 2016, firefighter Nick Howe was diagnosed with aggressive lymphoma. When other treatments failed, he joined a CAR-T trial at @NebraskaMed. He was in remission within weeks. Now, he’s giving back, raising funds for research & patient care. 🔗
Tweet media one
0
0
0
@OriBiotech
Oribiotech
22 days
After the @US_FDA's CGT roundtable, senior leaders have acknowledged what many already know. We won’t see widespread #PatientAccess without regulatory systems that support manufacturability and commercial viability from the start.
0
0
1